semaglutide off patent Off-patent in 2026: the next revolution in anti-obesity medications Indian pharma launches low-cost Ozempic
Description
They should ensure patients taking GLP-1 RAs are aware that cessation will likely lead to weight regain
A recent Washington Post
The FDAs decision was largely based on data from the SOUL trial, which included data from more than 9,000 patients who were randomized to oral Semaglutide or a placebo, & all patients had type 2 diabetes in addition to known ASCVD , CKD or both
Click here to know more.
One key finding: GLP-1 initiation among this group increased from 1.1% in 2020 to 7.3% in 2024
A recently published study found that social judgments extend beyond whether you lose weight or not, but also to how you do it.
